Research context
- Collected publications cover phage formulation stability, host-range characterization of an S. aureus phage, and human immune responses to therapeutic phages. [1] [2] [3]
Jon Iredell, MBBS PhD FRACP FRCPA FFScRCPA FASM
The Westmead Institute for Medical Research; The University of Sydney; Iredell LabProf Iredell originally trained as an intensivist and is one of the few Infectious Diseases physicians and the only formally qualified clinical Microbiologist with full professional membership of the ANZ Intensive Care Society. He is Director of the Centre for Infectious Diseases & Microbiology (CIDM) Laboratory Services, Westmead Hospital, Professor of Medicine and Microbiology (conjoint) at Sydney Medical School, senior staff microbiologist in NSW Pathology and NHMRC Practitioner Fellow since 2011. He has secured millions of research funding with infectious diseases focus.
Loading issues…
- Investing in the future of phage therapyThis week, we're republishing an article Dr. Jon Iredell and Jessica Sacher wrote for GARDP Revive, the Global Antibiotic Research & Development Partnership.
- State of the regulatory affair: Regulation of phage therapy in AustraliaThis week, phage researchers and clinicians from the Westmead Institute and Westmead Hospital brief us on how phage therapy is regulated in Australia, through the lens of their experience treating 14 patients with IV phage therapy.
